Harrow, Inc. (NASDAQ:HROW) Receives Consensus Rating of “Moderate Buy” from Analysts

Harrow, Inc. (NASDAQ:HROW) has been given a consensus rating of “Moderate Buy” by the ten brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $71.4286.

Several equities analysts have recently issued reports on HROW shares. Zacks Research lowered Harrow from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a research report on Wednesday, October 8th. Craig Hallum boosted their target price on Harrow from $54.00 to $64.00 and gave the stock a “buy” rating in a research note on Tuesday, September 23rd. BTIG Research restated a “buy” rating and issued a $63.00 price target on shares of Harrow in a research note on Wednesday, September 24th. Finally, LADENBURG THALM/SH SH lifted their price target on shares of Harrow from $64.00 to $66.00 and gave the company a “buy” rating in a report on Wednesday, November 12th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Teacher Retirement System of Texas increased its holdings in Harrow by 4.1% in the 2nd quarter. Teacher Retirement System of Texas now owns 8,478 shares of the company’s stock worth $259,000 after purchasing an additional 332 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Harrow by 2.1% during the second quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company’s stock worth $505,000 after purchasing an additional 341 shares during the last quarter. Alliancebernstein L.P. increased its stake in shares of Harrow by 1.7% in the third quarter. Alliancebernstein L.P. now owns 29,520 shares of the company’s stock valued at $1,422,000 after buying an additional 500 shares during the period. Pale Fire Capital SE raised its holdings in Harrow by 6.8% in the 2nd quarter. Pale Fire Capital SE now owns 8,683 shares of the company’s stock valued at $265,000 after buying an additional 550 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Harrow by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock worth $483,000 after buying an additional 790 shares during the period. 72.76% of the stock is currently owned by institutional investors.

Harrow Price Performance

Shares of NASDAQ:HROW opened at $50.09 on Monday. The firm has a 50 day moving average of $41.78 and a 200-day moving average of $38.83. Harrow has a 12 month low of $20.85 and a 12 month high of $51.30. The company has a current ratio of 2.72, a quick ratio of 2.52 and a debt-to-equity ratio of 5.21. The stock has a market capitalization of $1.86 billion, a PE ratio of -500.85 and a beta of 0.07.

Harrow (NASDAQ:HROW) last announced its quarterly earnings data on Monday, November 10th. The company reported $0.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.11. Harrow had a negative net margin of 1.99% and a positive return on equity of 28.71%. The business had revenue of $71.64 million for the quarter, compared to analysts’ expectations of $73.70 million. On average, equities research analysts predict that Harrow will post -0.53 EPS for the current fiscal year.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.